including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View more
The annual global premier event in nuclear medicine and molecular imaging, the 2026 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), has officially kicked off.
View moreCurium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology
PET/CT predicts response to neoadjuvant therapy in breast cancer
Half-Life, High Cost, High Stakes: Radiopharmaceuticals in Oncology Practice
The Quarter That Powers Nuclear Medicine: Why Accelerator Targets May Be the Most Important Components You've Never Heard Of
South Korea Bets on Domestic Lu-177 Production as It Builds Its Radiopharmaceutical Supply Chain
Archeus Technologies Reconstitutes Advisory Board to Advance Clinical-Stage Radiopharmaceutical Pipeline
